Yahoo Finance

Baird lowered the firm’s price target on Editas Medicine (EDIT) to $8 from $10 and keeps an Outperform rating on the shares. The firm said they expect the shares could move higher as the in vivo programs move towards the clinic and clinical data nears, though it could be a number of quarters before momentum begins to build.

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on EDIT:

• Editas Medicine price target lowered to $3 from $5 at Barclays

• Editas Medicine downgraded to Hold from Buy at Truist

• Editas Medicine downgraded to Hold from Buy at Stifel

• Editas Medicine Shifts Focus to In Vivo Gene Editing

• Editas to reduce workforce by 65%, announces departure of CMO Baisong Mei